<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535092</url>
  </required_header>
  <id_info>
    <org_study_id>LEG-SIL-LTX-03</org_study_id>
    <nct_id>NCT01535092</nct_id>
  </id_info>
  <brief_title>Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Legalon SIL for the Treatment of HCV Recurrence of the Graft in Orthotopic Liver Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Orthotopic liver transplantation (OLT) is the treatment of choice for patients with Hepatitis
      C Virus (HCV) infection and end-stage liver disease or hepatocellular carcinoma; infection of
      the graft and hepatitis C recurrence is universal after OLT and recurrent HCV hepatitis often
      follows an accelerated course after OLT, with rapid histological recurrence and cirrhosis.
      These very poor outcome significantly affect graft and patient survival and reduces the
      benefit of transplantation for this indication. Therapeutic strategies are not available;
      high viral load, high prevalence of genotype 1b and need of dose reduction of interferon and
      ribavirin because of the side effects or intolerance, together with the interference of
      immunosuppressive drugs, resulted in the vast majority of the patients in failure in
      obtaining viral eradication.

      Recently, Silibinin, has been studied and reported to be capable to act as potent antiviral
      agent in patients with HCV; it has been used successfully in a protocol of a 14 day
      intravenous infusion in previous non-responders to peginterferon/ribavirin therapy. In view
      of his postulated profile of safety, it seems an ideal drug to be used in the setting of HCV
      recurrent patients after liver transplant.

      Aim of this prospective, randomized, double-blind, placebo-controlled, parallel group study
      is to determine the therapeutic effect of Legalon SIL in the prevention of HCV reinfection in
      chronically infected hepatitis C patients after OLT.

      Awaiting orthotopic liver transplantation patients affected by HCV will be randomised 3:1 to
      receive, in addition to their current therapy, silibinin 20mg/kg/day (Legalon SIL) or placebo
      infused over 2 hours from 14 to 21 consecutive days; in addition, patients will receive
      treatment with silibinin 20mg/kg/day (Legalon SIL), infused over 2 hours, for 7 days after
      transplant.

      The Primary Efficacy endpoint is to achieve sustained virological response (SVR) while
      Secondary Efficacy endpoints are to evaluate the virologic response, the percentage of
      patients who has a decreased of at least 2 log10 the levels of HCV-RNA and the safety of
      Legalon SIL in this population.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    when realized that the target 60% of patients with SVR was no more achievable
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response (SVR), defined as Virological Response (undetectable HCV-RNA) that lasts 6 months after the transplant</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic response (VR) defined as undetectable HCV RNA</measure>
    <time_frame>after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who has a decreased of at least 2 log10 the levels of HCV-RNA</measure>
    <time_frame>at week 4 after OLT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with AE</measure>
    <time_frame>after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory parameters</measure>
    <time_frame>after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood levels of immunosuppressive drugs</measure>
    <time_frame>week 1, 2, 3, 4, 8, 12, 24 after OLT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>after 14-21 days of pre-OLT and 7 days of post-OLT treatment; week 2, 3, 4, 8, 12, 24 after OLT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>HCV Recurrence After Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>silibinin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silibinin</intervention_name>
    <description>20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT</description>
    <arm_group_label>silibinin</arm_group_label>
    <other_name>Legalon SIL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must provide signed and dated informed consent before undergoing any trial
             related procedure.

          2. Patient between 18 and 70 years of age.

          3. Patient must have documented HCV infection. The HCV-RNA result obtained from the local
             laboratory at the screening visit must confirm HCV-RNA &gt; 1000 IU/mL.

          4. Patient must qualify for liver transplantation at the time of Screening according to
             Model for End stage Liver Disease (MELD) criteria

          5. Patient must have a documented diagnosis of cirrhosis.

          6. Patient weigh between 50 kg and 100 kg.

          7. Patients must be able to communicate, participate and comply with the requirements of
             the entire study.

          8. Female patients of child-bearing potential must agree on using a contraceptive method
             (oral contraceptive, intrauterine device, transdermal contraceptive patch) and must
             have a negative pregnancy urine test at screening.

          9. HCV Genotype, chest X-ray, ultrasonography and ocular examination (for patients with
             history of diabetes or hypertension) must be performed within 6 months prior to
             Screening or between Screening and Day 1. 12-Lead ECG must be performed within 3
             months prior to Screening.

        Exclusion Criteria:

          1. Patients known to be coinfected with the human immunodeficiency virus (HIV) or
             hepatitis B virus (HBsAg positive).

          2. Active septic infections at time of screening.

          3. Previous organ transplantation other than cornea and hair.

          4. Use of systemic immunosuppressant or immunomodulating agents (including systemic
             corticosteroids) within 4 weeks of the screening visit or during the screening period.

          5. Treatment for HCV with any investigational medication (prior use of silymarin is not
             exclusionary)

          6. Treatment for HCV with any licensed therapies or prior maintenance therapy with any
             interferon alpha within 30 days of the randomization visit.

          7. Participation in any other clinical trial within 30 days of randomization or intention
             to participate in another clinical trial during participation in this study.

          8. Any known pre-existing medical condition that could interfere with the subject's
             participation in and completion of the study including but not limited to:

               -  Chronic pulmonary disease (eg, clinical chronic obstructive pulmonary disease,
                  interstitial lung disease, pulmonary fibrosis, sarcoidosis).

               -  Current or history of any clinically significant cardiac
                  abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial
                  infarction, pulmonary hypertension, complex congenital heart disease,
                  cardiomyopathy, significant arrhythmia) including current uncontrolled
                  hypertension, or history of use of antianginal agents for cardiac conditions.

               -  Any other condition which, in the opinion of a physician-investigator, would make
                  the patient unsuitable for enrollment or could interfere with the subject
                  participating in and completing the study.

          9. Subjects who are part of the site personnel directly involved with this study or those
             who are family members of the investigational study staff.

         10. If female, pregnancy or breast-feeding.

         11. Known hypersensitivity to LegalonÂ® SIL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Forns, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Barcelona</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV recurrence</keyword>
  <keyword>HCV reinfection</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Legalon SIL</keyword>
  <keyword>silibinin</keyword>
  <keyword>viral load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
    <mesh_term>Silybin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 5, 2015</submitted>
    <returned>March 14, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

